Antibodies and antibody fragments are also promising FGFR blockers, as in the case of FGFR1‐targeting scFvD2‐Fc , which both alone and coupled with the cytotoxic drug monomethyl auristatin E, showed very strong inhibition of FGFR1‐dependent lung cancer cell lines 13. Here, FGFR1 is linked to lung carcinoma.